No connection

Search Results

CCEL vs UNH

CCEL
Cryo-Cell International, Inc.
BEARISH
Price
$3.67
Market Cap
$29.6M
Sector
Healthcare
AI Confidence
95%
UNH
UnitedHealth Group Incorporated
NEUTRAL
Price
$323.48
Market Cap
$293.61B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
CCEL
--
UNH
24.43
Forward P/E
CCEL
183.5
UNH
16.08
P/B Ratio
CCEL
-1.61
UNH
3.11
P/S Ratio
CCEL
0.95
UNH
0.66
EV/EBITDA
CCEL
31.86
UNH
16.47

Profitability

Gross Margin
CCEL
63.53%
UNH
18.53%
Operating Margin
CCEL
9.96%
UNH
0.34%
Profit Margin
CCEL
-8.52%
UNH
2.69%
ROE
CCEL
--
UNH
12.54%
ROA
CCEL
0.19%
UNH
3.9%

Growth

Revenue Growth
CCEL
-3.6%
UNH
12.3%
Earnings Growth
CCEL
-80.5%
UNH
-99.9%

Financial Health

Debt/Equity
CCEL
--
UNH
0.82
Current Ratio
CCEL
0.62
UNH
0.79
Quick Ratio
CCEL
0.55
UNH
0.7

Dividends

Dividend Yield
CCEL
16.35%
UNH
2.73%
Payout Ratio
CCEL
3962.91%
UNH
65.99%

AI Verdict

CCEL BEARISH

CCEL exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price/Book ratio of -1.61, suggesting negative shareholder equity. The company's dividend is fundamentally unsustainable with a payout ratio of 3962.91%, indicating that dividends are being paid out of capital or debt rather than earnings. While gross margins remain strong, the combination of declining YoY revenue (-3.60%) and crashing earnings growth (-80.50%) creates a precarious outlook. Liquidity is a critical concern with a current ratio of 0.62, placing the firm at significant short-term financial risk.

Strengths
Strong gross margins at 63.53%
Positive operating margin of 9.96%
Low Price/Sales ratio of 0.95
Risks
Negative equity as indicated by Price/Book ratio of -1.61
Severe liquidity risk with a current ratio of 0.62 and quick ratio of 0.55
Unsustainable dividend payout ratio (3962.91%)
UNH NEUTRAL

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.

Strengths
Strong consistent revenue growth (12.3% YoY)
Manageable Debt/Equity ratio of 0.82
Attractive Forward P/E (16.08) compared to current P/E (24.43)
Risks
Extreme earnings volatility (YoY Earnings Growth -99.9%)
Poor liquidity indicated by a Current Ratio of 0.79
Extremely thin operating margins (0.34%)

Compare Another Pair

CCEL vs UNH: Head-to-Head Comparison

This page compares Cryo-Cell International, Inc. (CCEL) and UnitedHealth Group Incorporated (UNH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile